Shanghai, May 14, 2024 – We are excited to announce that our cutting-edge product, ColonAiQ® – a targeted gene methylation combined detection reagent kit using the PCR-fluorescence probe method, has
The US Food and Drug Administration (FDA) has granted breakthrough device designation to Singlera Genomics’ PDACatch liquid biopsy assay. The new DNA methylation-based assay is intended to identify pancreatic adenocarcinoma in individuals
Singlera Genomics, Inc. is thrilled to announce a significant milestone in our journey toward revolutionizing genetic and genomic analysis. Our pioneering efforts have been officially recognized with the awarding of
Saver’s Med Pte Ltd is the exclusive distributor for Singlera’s ColonAiQ® in Singapore and the Philippines.
ColonAiQ is undergoing Health Sciences Authority (HSA) review for registration in Singapore and the Philippines.
Sign up for our waitlist to be among the first to be notified when ColonAiQ becomes available! Please leave your contact details.